Harrow, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 27, 2019, by Harrow Health, Inc. (the "Company"). The report details the termination of a material definitive agreement and the subsequent restructuring of its wholly-owned subsidiary, Park Compounding, Inc. ("Park").
Key Financial Metrics and Material Changes
The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period. Instead, it focuses on the financial impact of a specific restructuring event:
- Transaction Termination: On August 30, 2019, the Company terminated an Asset Purchase Agreement with Noice Rx, LLC. The sale of Park's non-ophthalmology compounding assets failed to close because the California State Board of Pharmacy did not issue the required temporary license to the buyer.
- Operational Cessation: Park ceased operations at the Irvine, California facility on August 27, 2019.
- Restructuring Costs: The Company expects to incur approximately $4,500,000 in non-cash impairment costs related to property, plant, equipment, goodwill, and intangible assets. Additionally, one-time cash costs for severance and other restructuring activities are estimated between $300,000 and $500,000.
- Revenue Impact: The Company plans to reduce the Park product formulary to approximately seven SKUs. It expects to retain approximately 50% of Park's revenue by transitioning formulations to its New Jersey-based facilities (ImprimisRx, LLC).
Outlook, Management Commentary, and Risks
Management anticipates that if the restructuring is successfully executed and the Company retains half of Park's revenue, there will be no material change to consolidated operating earnings or cash produced from operations on a forward-looking basis. All compounding business will be consolidated into ImprimisRx, LLC.
Risks and Contingencies: The filing includes a cautionary note regarding forward-looking statements. Actual results may differ due to challenges with reorganization activities. The Company is under no duty to update these statements.
Investor Verification Checklist
- Verify the exact timing and magnitude of the $4.5 million non-cash impairment charge in the upcoming quarterly report.
- Confirm the actual revenue retention rate from the Park business versus the projected 50% target.
- Monitor the successful transition of compounded formulations to the New Jersey facilities.
- Review the impact of the $300,000-$500,000 severance costs on the Company's cash flow for the fiscal year ending December 31, 2019.